A Clinical Trial to Assess the Effect of Deforolimus (AP23573; MK-8669) on QTc Interval in Patients (Protocol 037).

Trial Profile

A Clinical Trial to Assess the Effect of Deforolimus (AP23573; MK-8669) on QTc Interval in Patients (Protocol 037).

Completed
Phase of Trial: Phase I

Latest Information Update: 08 May 2014

At a glance

  • Drugs Ridaforolimus (Primary)
  • Indications Cancer
  • Focus Pharmacodynamics
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 14 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 14 May 2010 Actual patient number (23) added as reported by ClinicalTrials.gov.
    • 28 Apr 2010 Planned end date changed from 1 May 2010 to 1 Apr 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top